Evolocumab alleviates atherogenesis by inhibiting inflammation-mediated endothelial cell activation via the PI3K/AKT/NF-κB pathway - PubMed
4 hours ago
- #PI3K/AKT/NF-κB pathway
- #endothelial cell activation
- #atherosclerosis
- Evolocumab (Evb) alleviates atherosclerosis by inhibiting inflammation-mediated endothelial cell activation via the PI3K/AKT/NF-κB pathway.
- In vivo studies showed Evb reduced atherosclerotic lesions and inflammation in ApoE-/- mice on a Western diet.
- In vitro, Evb suppressed LPS-induced VCAM-1 overexpression in HUVECs and inhibited the PI3K/AKT/NF-κB pathway.
- VCAM-1 levels were positively correlated with PCSK9 in plasma and carotid plaque samples from patients with carotid artery stenosis.
- VCAM-1 and PCSK9 protein expression was higher in carotid arteries with plaques compared to those without.
- The study suggests Evb's mechanism involves regulating endothelial cell activation to mitigate atherosclerosis.